Latest news
SciSparc’s NeuroThera Launches Phase IIb Tourette Trial at Yale Child Study Center - TipRanksTipRanks · Thu, 06 Aug 2026 06:21:58 GMTNeuroThera Launches Phase IIb Trial at Yale for Novel Tourette Treatment - citybuzz.cocitybuzz.co · Thu, 06 Aug 2026 00:24:05 GMTNeuroThera Labs Expands Tourette Drug Trial to Yale in Phase IIb Study - TipRanksTipRanks · Wed, 05 Aug 2026 18:36:37 GMTSciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock TitanStock Titan · Wed, 05 Aug 2026 13:00:51 GMTSciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 12:30:00 GMTTourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock TitanStock Titan · Wed, 05 Aug 2026 12:22:00 GMTSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb - GlobeNewswireGlobeNewswire · Wed, 05 Aug 2026 12:22:00 GMTPfizer raises 2026 guidance on underlying business growth, tilrekimig Phase III expansion - AllSciAllSci · Wed, 05 Aug 2026 09:27:45 GMT